People · Operator
Named in public records as an officer, director or promoter · active 2011–2024 · Other Health Care, Pharmaceuticals, Software / Tech, AI / ML, Manufacturing, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Convexity Scientific Inc. | — | Other Health Care | Series B | $37.8M | $2.4M | 2019 |
| Torigen Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $10.9M | $62.0M | 2020 |
| Perosphere Technologies Inc. | — | Software / Tech | Series A | $7.5M | $50.5M | 2023 |
| Rapid Oxygen Co | — | Other Health Care | Seed | $4.5M | $12.4M | 2018 |
| Intelligent Clearing Network Inc | — | AI / ML | Seed | $3.1M | $20.0M | 2011 |
| Solais Lighting Inc | — | Manufacturing | Seed | $2.4M | $21.5M | 2011 |
| Affinimark Technologies Inc | — | Pharmaceuticals | Seed | $2.4M | $59.0M | 2016 |
| Oil Purifications Systems Inc | — | Other Technology | Seed | $1.1M | $38.8M | 2011 |
| Anne Arundel-SCA Surgicenter, LLC | — | Other Health Care | Pre-Seed | $999K | $1.8M | 2024 |
KEVIN CROWLEY at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside KEVIN CROWLEY on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Beatty | 1 | 400 |
| Richard L. Sharff, Jr. | 1 | 72 |
| Mark Smith | 1 | 28 |
| Christopher Brown | 1 | 16 |
| Stephen Bruso | 1 | 9 |
| Steve Johnson | 1 | 8 |
| Kevin Rakin | 1 | 7 |
| JONATHAN MURRAY | 1 | 7 |
| Harry H Penner, Jr. | 1 | 6 |
| JAMES PETRAS | 1 | 6 |
| WILLIAM COWEN | 1 | 5 |
| John Kallassy | 1 | 4 |
| Richard Wilmot | 1 | 4 |
| Timothy Davis | 1 | 3 |
| Kris Lowther | 1 | 3 |
| Ralph Finger | 1 | 3 |
| Rafael Castilla | 1 | 3 |
| Solomon Steiner | 1 | 3 |
| Timothy C. Davis | 1 | 2 |
| Elizabeth Galbut | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.